OverviewChartNewsTraderScreen

BNP Paribas Aktienanleihe SNW 27..../  DE000PC1XVS6  /

Frankfurt Zert./BNP
2024-04-26  9:40:18 PM Chg.+0.320 Bid9:59:52 PM Ask9:59:52 PM Underlying Strike price Expiration date Option type
98.880EUR +0.32% 98.770
Bid Size: 20,000		 98.870
Ask Size: 20,000		 SANOFI SA INHABER ... 90.00 EUR 2024-06-27 Call
TeleTrader 04-25 Europe opens mostly down after corporate earnings
TeleTrader 04-25 Europe down in premarket as financial results pour in
TeleTrader 04-25 Sanofi books net sales of €10.5B in Q1, up 2.4%
GlobeNewswire 04-25 Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire 04-23 Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire 04-17 IGM Biosciences Announces Refocusing of Sanofi Collaboration
GlobeNewswire 04-17 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire 04-16 2024 DTA Summit Agenda is LIVE!!
GlobeNewswire 04-10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire 04-09 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...
GlobeNewswire 03-29 Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 03-22 Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
GlobeNewswire 03-14 MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Busi...
GlobeNewswire 03-14 SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
GlobeNewswire 03-11 Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance ...
GlobeNewswire 03-05 Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (F...
GlobeNewswire 02-28 Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized ...
GlobeNewswire 02-27 Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...
GlobeNewswire 02-24 Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significa...
GlobeNewswire 02-23 Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” co...
GlobeNewswire 02-23 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire 02-23 Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inf...
GlobeNewswire 02-22 Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoi...
GlobeNewswire 02-22 Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Bus...
GlobeNewswire 02-16 Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)